2025 Q4 -tulosraportti
93 päivää sitten
‧23 min
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 2 688 | - | - | ||
| 226 | - | - | ||
| 1 586 | - | - | ||
| 414 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 päivää sittenNow it is actually time that Lytix provides an update on when Verrica intends to start phase 3! They can no longer hide behind not knowing anything or not being able to communicate anything, they certainly know something and owe the shareholders a statement! How long can Verrica continue with this game and the dragging out of time without Lytix doing something about it? It's fine that they have full control over the study, but Lytix must surely have something to say? They have hired a bunch of competent people from the pharmaceutical industry last year, but we are at a standstill! Not exactly what one expected based on the statement that they would accelerate quickly forward in May last year!
·10.5. · MuokattuThe quarterly presentation is finally approaching again on May 21st, where there's a chance to get Rekdal and Breistein to speak and answer questions. Those of you who are shareholders are welcome to engage by sending an email to Lytix (post@lytixbiopharma.com) to get management to provide the market with greater clarity on some of this: - It's almost 2 years since Verrica's Phase 2 data was presented. It's 1 year since alignment with the FDA on a very simple and cheap Phase 3 came, but Verrica will not finance it. Why not when they have an owner with very deep pockets? This cannot be reassuring for a partner either. Does Paul B. Manning not believe that VP315 will be lucrative after all? - For how many years after the Phase 2 data came can VP315 lie fallow before the rights will be taken back from Verrica? - It's 1 year since Lytix announced a new strategy for acceleration towards commercialization from then. Why make a fool of the shareholders in this way? No own studies are ongoing, and everything else is delayed (Verrica's Phase 3 is lying fallow, NeoLipa with top-line is constantly delayed due to poor recruitment, Phase 1 LTX401 is delayed until 2027). What is the plan going forward? When and what will accelerate? - Must Top-line data for NeoLipa (the company's key value driver) be postponed yet again until summer 2027, or have more than 20 of 27 patients been recruited now? A new hospital for faster recruitment was promised to be in place by March this year. Is this delayed or shelved? - How much are the data (the key value driver) weakened when it takes 2 years to recruit a few patients in such a common cancer type? BP will clearly see this and question whether healthier patients were cherry-picked to get better results compared to historical data. - Patent terms are eaten up year by year with delays. Why not faster development – acceleration? When can one expect to receive answers to patent applications pending for LTX401? - How many years should shareholders expect it will take before data from Phase 2 studies with LTX401 can be seen? Under 5 years from now is perhaps unrealistic, but under 7 years might be possible? - Why is the company using sorely needed cash reserves to advertise in Finansavisen and Kapital? It is obviously to attract fresh capital via new investors – when is the next share issue? - What is the strategy regarding financing? Cancer research is expensive. Does management have any idea how many 100 million shareholders must expect to be raised in share issues going forward before Lytix can stand on its own feet via funding from a partner, or do they just keep going as long as possible? - Is it relevant to proceed with Phase 3 independently within malignant melanoma when top-line data from NeoLipa becomes available, or will it be put on hold until a partner can be found? - What will happen going forward after NeoLipa, and what is being worked on today? One is waiting for data for the key value driver, and then one must wait for a partner agreement to hopefully be concluded perhaps 9-18 months after top-line data is available? Shouldn't more activity be started to accelerate?·12.5.What worries me is the total lack of buyers, even though we are to get a lot of info now in the next 3 weeks! I sincerely hope that Lytix at ASCO manages to deliver so we can put this jiggling around 10 kroner behind us for good, if they don't deliver I'm afraid that we will fall sharply back! Same if Verrica doesn't manage to give a timeline today on when they will start Phase 3!
·6.5.Update from Redeye after today's announcement: "...This demonstrates the immunological activity of ruxotemitide in BCC, setting it apart from most competitors (such as chemotherapy-based skin creams). We believe the main advantage is the potential protection against new lesions. The immunological effects suggest that all patients have been vaccinated against antigens present in the injected lesion. This would likely justify premium pricing and be extra useful for patients with recurring lesions. However, larger, more specific studies are needed to demonstrate that this is the case." https://www.redeye.se/research/1164510/lytix-biopharma-abscopal-effects-also-in-bcc?notificationId=dc343f69-33b5-4ec0-b6a4-81d71f9a2157- ·6.5. · MuokattuUpdate from DNB/Carnegie after today's announcement: Lytix’s partner Verrica Pharmaceuticals will present additional data from the completed Phase II study of VP-315 (ruxotemitide) in BCC patients at the 2026 Society for Investigative Dermatology (SID) Annual Meeting next week. This includes new, encouraging findings suggesting VP-315 induces abscopal (systemic) effects following local administration. We believe the new data adds further strength to the case for the treatment's potential in this indication and reiterate our fair value of NOK14–18 per share. https://access.dnbcarnegie.com/publication/49ea4157-977c-44ae-f411-08deaa8dfd35
- ·6.5.Good rise for Verrica yesterday, 12.58%
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
93 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenNow it is actually time that Lytix provides an update on when Verrica intends to start phase 3! They can no longer hide behind not knowing anything or not being able to communicate anything, they certainly know something and owe the shareholders a statement! How long can Verrica continue with this game and the dragging out of time without Lytix doing something about it? It's fine that they have full control over the study, but Lytix must surely have something to say? They have hired a bunch of competent people from the pharmaceutical industry last year, but we are at a standstill! Not exactly what one expected based on the statement that they would accelerate quickly forward in May last year!
- ·10.5. · MuokattuThe quarterly presentation is finally approaching again on May 21st, where there's a chance to get Rekdal and Breistein to speak and answer questions. Those of you who are shareholders are welcome to engage by sending an email to Lytix (post@lytixbiopharma.com) to get management to provide the market with greater clarity on some of this: - It's almost 2 years since Verrica's Phase 2 data was presented. It's 1 year since alignment with the FDA on a very simple and cheap Phase 3 came, but Verrica will not finance it. Why not when they have an owner with very deep pockets? This cannot be reassuring for a partner either. Does Paul B. Manning not believe that VP315 will be lucrative after all? - For how many years after the Phase 2 data came can VP315 lie fallow before the rights will be taken back from Verrica? - It's 1 year since Lytix announced a new strategy for acceleration towards commercialization from then. Why make a fool of the shareholders in this way? No own studies are ongoing, and everything else is delayed (Verrica's Phase 3 is lying fallow, NeoLipa with top-line is constantly delayed due to poor recruitment, Phase 1 LTX401 is delayed until 2027). What is the plan going forward? When and what will accelerate? - Must Top-line data for NeoLipa (the company's key value driver) be postponed yet again until summer 2027, or have more than 20 of 27 patients been recruited now? A new hospital for faster recruitment was promised to be in place by March this year. Is this delayed or shelved? - How much are the data (the key value driver) weakened when it takes 2 years to recruit a few patients in such a common cancer type? BP will clearly see this and question whether healthier patients were cherry-picked to get better results compared to historical data. - Patent terms are eaten up year by year with delays. Why not faster development – acceleration? When can one expect to receive answers to patent applications pending for LTX401? - How many years should shareholders expect it will take before data from Phase 2 studies with LTX401 can be seen? Under 5 years from now is perhaps unrealistic, but under 7 years might be possible? - Why is the company using sorely needed cash reserves to advertise in Finansavisen and Kapital? It is obviously to attract fresh capital via new investors – when is the next share issue? - What is the strategy regarding financing? Cancer research is expensive. Does management have any idea how many 100 million shareholders must expect to be raised in share issues going forward before Lytix can stand on its own feet via funding from a partner, or do they just keep going as long as possible? - Is it relevant to proceed with Phase 3 independently within malignant melanoma when top-line data from NeoLipa becomes available, or will it be put on hold until a partner can be found? - What will happen going forward after NeoLipa, and what is being worked on today? One is waiting for data for the key value driver, and then one must wait for a partner agreement to hopefully be concluded perhaps 9-18 months after top-line data is available? Shouldn't more activity be started to accelerate?·12.5.What worries me is the total lack of buyers, even though we are to get a lot of info now in the next 3 weeks! I sincerely hope that Lytix at ASCO manages to deliver so we can put this jiggling around 10 kroner behind us for good, if they don't deliver I'm afraid that we will fall sharply back! Same if Verrica doesn't manage to give a timeline today on when they will start Phase 3!
- ·6.5.Update from Redeye after today's announcement: "...This demonstrates the immunological activity of ruxotemitide in BCC, setting it apart from most competitors (such as chemotherapy-based skin creams). We believe the main advantage is the potential protection against new lesions. The immunological effects suggest that all patients have been vaccinated against antigens present in the injected lesion. This would likely justify premium pricing and be extra useful for patients with recurring lesions. However, larger, more specific studies are needed to demonstrate that this is the case." https://www.redeye.se/research/1164510/lytix-biopharma-abscopal-effects-also-in-bcc?notificationId=dc343f69-33b5-4ec0-b6a4-81d71f9a2157
- ·6.5. · MuokattuUpdate from DNB/Carnegie after today's announcement: Lytix’s partner Verrica Pharmaceuticals will present additional data from the completed Phase II study of VP-315 (ruxotemitide) in BCC patients at the 2026 Society for Investigative Dermatology (SID) Annual Meeting next week. This includes new, encouraging findings suggesting VP-315 induces abscopal (systemic) effects following local administration. We believe the new data adds further strength to the case for the treatment's potential in this indication and reiterate our fair value of NOK14–18 per share. https://access.dnbcarnegie.com/publication/49ea4157-977c-44ae-f411-08deaa8dfd35
- ·6.5.Good rise for Verrica yesterday, 12.58%
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 2 688 | - | - | ||
| 226 | - | - | ||
| 1 586 | - | - | ||
| 414 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
2025 Q4 -tulosraportti
93 päivää sitten
‧23 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 21.5. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 13.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 päivää sittenNow it is actually time that Lytix provides an update on when Verrica intends to start phase 3! They can no longer hide behind not knowing anything or not being able to communicate anything, they certainly know something and owe the shareholders a statement! How long can Verrica continue with this game and the dragging out of time without Lytix doing something about it? It's fine that they have full control over the study, but Lytix must surely have something to say? They have hired a bunch of competent people from the pharmaceutical industry last year, but we are at a standstill! Not exactly what one expected based on the statement that they would accelerate quickly forward in May last year!
- ·10.5. · MuokattuThe quarterly presentation is finally approaching again on May 21st, where there's a chance to get Rekdal and Breistein to speak and answer questions. Those of you who are shareholders are welcome to engage by sending an email to Lytix (post@lytixbiopharma.com) to get management to provide the market with greater clarity on some of this: - It's almost 2 years since Verrica's Phase 2 data was presented. It's 1 year since alignment with the FDA on a very simple and cheap Phase 3 came, but Verrica will not finance it. Why not when they have an owner with very deep pockets? This cannot be reassuring for a partner either. Does Paul B. Manning not believe that VP315 will be lucrative after all? - For how many years after the Phase 2 data came can VP315 lie fallow before the rights will be taken back from Verrica? - It's 1 year since Lytix announced a new strategy for acceleration towards commercialization from then. Why make a fool of the shareholders in this way? No own studies are ongoing, and everything else is delayed (Verrica's Phase 3 is lying fallow, NeoLipa with top-line is constantly delayed due to poor recruitment, Phase 1 LTX401 is delayed until 2027). What is the plan going forward? When and what will accelerate? - Must Top-line data for NeoLipa (the company's key value driver) be postponed yet again until summer 2027, or have more than 20 of 27 patients been recruited now? A new hospital for faster recruitment was promised to be in place by March this year. Is this delayed or shelved? - How much are the data (the key value driver) weakened when it takes 2 years to recruit a few patients in such a common cancer type? BP will clearly see this and question whether healthier patients were cherry-picked to get better results compared to historical data. - Patent terms are eaten up year by year with delays. Why not faster development – acceleration? When can one expect to receive answers to patent applications pending for LTX401? - How many years should shareholders expect it will take before data from Phase 2 studies with LTX401 can be seen? Under 5 years from now is perhaps unrealistic, but under 7 years might be possible? - Why is the company using sorely needed cash reserves to advertise in Finansavisen and Kapital? It is obviously to attract fresh capital via new investors – when is the next share issue? - What is the strategy regarding financing? Cancer research is expensive. Does management have any idea how many 100 million shareholders must expect to be raised in share issues going forward before Lytix can stand on its own feet via funding from a partner, or do they just keep going as long as possible? - Is it relevant to proceed with Phase 3 independently within malignant melanoma when top-line data from NeoLipa becomes available, or will it be put on hold until a partner can be found? - What will happen going forward after NeoLipa, and what is being worked on today? One is waiting for data for the key value driver, and then one must wait for a partner agreement to hopefully be concluded perhaps 9-18 months after top-line data is available? Shouldn't more activity be started to accelerate?·12.5.What worries me is the total lack of buyers, even though we are to get a lot of info now in the next 3 weeks! I sincerely hope that Lytix at ASCO manages to deliver so we can put this jiggling around 10 kroner behind us for good, if they don't deliver I'm afraid that we will fall sharply back! Same if Verrica doesn't manage to give a timeline today on when they will start Phase 3!
- ·6.5.Update from Redeye after today's announcement: "...This demonstrates the immunological activity of ruxotemitide in BCC, setting it apart from most competitors (such as chemotherapy-based skin creams). We believe the main advantage is the potential protection against new lesions. The immunological effects suggest that all patients have been vaccinated against antigens present in the injected lesion. This would likely justify premium pricing and be extra useful for patients with recurring lesions. However, larger, more specific studies are needed to demonstrate that this is the case." https://www.redeye.se/research/1164510/lytix-biopharma-abscopal-effects-also-in-bcc?notificationId=dc343f69-33b5-4ec0-b6a4-81d71f9a2157
- ·6.5. · MuokattuUpdate from DNB/Carnegie after today's announcement: Lytix’s partner Verrica Pharmaceuticals will present additional data from the completed Phase II study of VP-315 (ruxotemitide) in BCC patients at the 2026 Society for Investigative Dermatology (SID) Annual Meeting next week. This includes new, encouraging findings suggesting VP-315 induces abscopal (systemic) effects following local administration. We believe the new data adds further strength to the case for the treatment's potential in this indication and reiterate our fair value of NOK14–18 per share. https://access.dnbcarnegie.com/publication/49ea4157-977c-44ae-f411-08deaa8dfd35
- ·6.5.Good rise for Verrica yesterday, 12.58%
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 000 | - | - | ||
| 2 688 | - | - | ||
| 226 | - | - | ||
| 1 586 | - | - | ||
| 414 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt